THE RELATIONSHIP BETWEEN MATERNAL ADIPOSITY AND INFANT WEIGHT GAIN AND CHILDHOOD WHEEZE AND ATOPY

Abstract

Background

Obesity and asthma have increased in westernised countries. Maternal obesity may increase childhood asthma risk. If this relation is causal it may be mediated through factors associated with maternal adiposity, such as fetal development, pregnancy complications or infant adiposity. We investigated the relationships of maternal BMI and fat mass with childhood wheeze and examined the influences of infant weight gain and childhood obesity.

Methods

Maternal pre-pregnancy BMI and estimated fat mass (from skinfold thicknesses) were related to asthma, wheeze and atopy in 940 children. Transient or persistent/late wheeze was classified using questionnaire data collected at ages 6, 12, 24 and 36 months and 6 years. At 6 years, skin prick testing was conducted and exhaled nitric oxide and spirometry measured. Infant adiposity gain was calculated from skinfold thickness at birth and 6 months.

Results

Greater maternal BMI and fat mass were associated with increased childhood wheeze (RR 1.08 per 5 kg m⁻², p=0.006; RR 1.09 per 10 kg, p=0.003); these reflected associations with transient wheeze (RR 1.11, p=0.003; RR 1.13, p=0.002, respectively) but not with persistent wheeze or asthma. Infant adiposity gain was associated with persistent wheeze but not significantly. Adjusting for infant adiposity gain or BMI at 3 or 6 years did not reduce the association between maternal adiposity and transient wheeze. Maternal adiposity was not associated with offspring atopy, exhaled nitric oxide, or spirometry.

Discussion

Greater maternal adiposity is associated with transient wheeze but not asthma or atopy, suggesting effects upon airway structure/function but not allergic predisposition.

INTRODUCTION

In recent decades westernised countries have experienced increases in both obesity and respiratory disease, including asthma. These changes may reflect causal links or shared environmental or genetic factors. Increased asthma and asthma-like symptoms have been reported in association with adult(1) and childhood obesity.(2) Mechanisms have been proposed attributing this to anatomical, inflammatory or immunological consequences of obesity.(3, 4) There is evidence that children of obese women are at increased risk of asthma(5, 6) and wheeze,(7, 8) suggesting maternal obesity may affect respiratory or immune development.

Maternal pre-pregnancy weight has increased considerably in recent years, therefore potential adverse effects upon childhood health represent an important public health issue.(9) However, socioeconomic and lifestyle factors may confound the relationship between maternal adiposity and childhood wheeze.(10) Similarly, any such relationship may also be confounded by infant or childhood adiposity since maternal and child obesity are associated(11) and associations have been found between childhood obesity and asthma-like symptoms,(2) between rapid early weight gain and diminished infant lung function,(12) and between infant adiposity(13) or weight gain and early childhood wheeze.(13, 14) Further possible confounding factors include obesity-associated pregnancy complications such as preeclampsia, caesarean section, preterm birth and intrauterine growth restriction.(10, 15)

Wheeze risk at 18 months has been shown to increase with increasing maternal pre-pregnancy body mass index (BMI),(7) the contribution of pregnancy complications to this association was found to be small. Recently, an association between maternal pre-pregnancy BMI and current asthma in children at age 15-16 years was reported, suggesting that adverse effects of maternal obesity might persist throughout childhood.(5) Although large, these studies used reported pre-pregnancy weight, and childhood lung function and atopy were not measured. Measures of fat mass may potentially represent maternal adiposity better than BMI. This study is the first to explore the relationship between maternal fat mass and childhood asthma and wheeze alongside objective measurements of atopy and lung function.

METHODS

Participants

Participants were mothers and children from the Southampton Women’s Survey.(16) Women aged 20-34 years were recruited during 1998-2002. Women were interviewed and anthropometric measurements made at recruitment and, for those who became pregnant, at 11 and 34 weeks of pregnancy. Childhood follow-up visits occurred at 6, 12, 24 and 36 months. During 2006-2010 1529 children aged 6 years were invited for respiratory follow-up. Home-based questionnaire, skin test and spirometry data were collected from 940 children. Participants were encouraged to attend the clinic for exhaled nitric oxide (eNO) testing, 596 did so but time and resources meant that not all participants attended. Maternal pre-pregnancy fat mass and BMI measurements were available for 927 (98.6 %) and 930 (98.9 %) women respectively (Figure 1). Parental consent was obtained and local ethical approval was granted (276/97, 307/97, 089/99, 06/Q1702/104).

Figure 1.

Flow of participants through the study

Maternal anthropometry

Pre-pregnancy height and weight were measured using portable Seca 835 scales (Seca Ltd., Birmingham, UK) and Leicester stadiometer (Invicta Plastics Ltd., Leicester, UK). Biceps, triceps, suprailiac and subscapular skinfold thicknesses were measured with Harpenden ‘John Bull’ calipers (British Indicates Ltd., St Albans, UK). A standard protocol requiring three readings within 10% was followed. BMI was calculated as weight (kg)/(height (m))². Fat mass was estimated from body weight and skinfolds using the Durnin and Womersley equation.(17) Analysis was limited to pre-pregnancy measurements as body composition equations are not validated in pregnancy.

Childhood anthropometry

Research nurses measured subscapular skinfold thicknesses at birth and 6 months. Subscapular adiposity change conditional upon initial measurements was calculated using regression to account for exact age and regression to the mean. BMI at 3 and 6 years was calculated from height and weight and the values converted to age and gender specific z-scores using the Child Growth Foundation 1990 Reference (London, UK).

Atopy

Skin prick testing was conducted at age 6 years using cat, dog, house dust mite (Dermatophagoides pteronyssinus), egg, milk, grass and tree pollen allergens. A positive control of >3mm and negative control of 0mm was required. Any response ≥3 mm was considered evidence of atopy.

Childhood asthma and wheeze

Research nurses administered ISAAC core-questionnaire wheezing-module questions.(18) Mothers were asked whether their child had ‘ever been diagnosed with asthma by a doctor’ or had experienced ‘any episodes of chestiness associated with wheezing or whistling in his/her chest since they were last seen?’ Children who had ever been diagnosed with asthma and had experienced asthma symptoms or received asthma medication within the last year were considered to have current asthma; those reported to wheeze within the last year were considered to have current wheeze. Questionnaire data obtained at 6, 12, 24 and 36 months were combined with that from 6 years to define wheeze phenotypes based upon those of the Tuscon Children’s Respiratory Study(19):

• Transient wheeze: Wheeze ≤3 years but no wheeze or asthma treatment at 6 years.

• Persistent wheeze: Wheeze ≤3 years plus wheeze or asthma treatment at 6 years.

• Late-onset wheeze: No wheeze ≤3 years but wheeze or asthma treatment at 6 years.

Very few children had late-onset wheeze so the persistent and late-onset wheeze groups were combined.

Lung function

Spirometry was measured using a portable Koko spirometer with incentive software (KoKo v4; PDS Instrumentation; Louisville, USA). Measurements were made according to ATS guidelines,(20) although to avoid discomfort, nose-clips were not worn. Spirometry indices were standardised for height, gender and age using the growing lungs reference.(21)

Exhaled nitric oxide

Exhaled nitric oxide was measured according to ERS/ATS recommendations using a NIOX® chemiluminescence analyser (Aerocrine, Sweden).(22) A mean of three readings was calculated where possible. Values were normalised by inverse square root transformation then standardised. The sign was reversed so that high standardised scores represent high untransformed eNO values.

Statistical methods

Relative risks for binary outcomes were modelled using poisson regression with robust variance; poisson regression being appropriate for common outcomes where odds ratios cannot be interpreted as relative risks.(23) Children with transient or persistent/late wheeze were compared to children who had never wheezed. Linear regression was used for continuous outcomes. Relative risks and regression coefficients were expressed relative to 5 kg m⁻² change in BMI or 10 kg change in fat mass. Analyses were also conducted considering Maternal BMI as a discrete variable to classify women according to the world health organisation scheme as either normal weight (BMI 18.5-24.99), overweight (BMI 25-29.99) or obese (BMI ≥ 30) and considering maternal weight gain in pregnancy according to Institute of Medicine categories.

Potential confounders identified a priori were; maternal age, height, parity, education, socioeconomic status, smoking in pregnancy, asthma, eczema, rhinitis, and atopy and child’s gender, birthweight, gestation, and age at last breastfeed. Potential confounders were tested for association with each respiratory outcome. Model 1 included all variables associated with each outcome but excluded birth weight, gestation, adiposity gain in the first 6 months of life and the child’s BMI at age 6 years as each of these may lie on the causal pathway. Model 2 included birthweight and gestation if they were significantly associated with the outcomes and further analyses were conducted adjusting for all significantly associated confounders (including birthweight and gestation) and infant adiposity gain (birth-6 months) (Model 3) and child’s BMI aged 6 (Model 4).

Based upon effect sizes of approaching 5% seen in previous studies we estimated approaching 100% power to detect an increase in risk of this magnitude per kg maternal fat mass and of 80-100% per BMI unit dependent upon physiological outcome. Bonferroni correction was considered over-conservative as the analyses were designed a priori to test a limited number of hypotheses and not all the tests were independent.(24) We focused our interest on results with P-values ≤0.01 and considered consistency of the findings in our interpretation. Stata® 11 (Stata Corp., College Station, TX) was used for all analyses.

RESULTS

Participants

Participating mothers were similar to non-participants in terms of body composition, asthma and atopy, however, they were slightly older, taller, less likely to smoke in pregnancy, more likely to be primiparous and were of higher educational attainment and social class. Participating children were of similar birthweight and gestation compared with those not followed up (Table 1). When compared with the children attending the clinic, children unable to attend did not differ significantly (data not shown).

Table 1.

Comparison of SWS mother-child pairs with complete data with those lacking either maternal body composition or 6-year follow-up data but born in the same time period.

		Participating mother-child pairs (n= 940)	Mother-child pairs with missing data (n=589)	P-value
Maternal characteristics
Age at child's birth, years (mean (SD))		30.3 (3.8)	29.7 (3.8)	0.007
Primiparous (n (%))
No		494 (52.6)	355 (60.3)	0.003
Yes		446 (47.5)	234 (39.7)
Qualifications (n (%))	None	15 (1.6)	36 (6.1)	<0.001
	GCSE D-G	88 (9.4)	67 (11.4)
	GCSE A*-C	278 (29.6)	165 (28.1)
	A Level	270 (28.8)	175 (29.8)
	HND	66 (7.0)	39 (6.6)
	Degree	222 (23.6)	106 (18.0)
Parents’ social class (n (%))	I	100 (10.8)	52 (12.3)	0.019
	II	454 (48.8)	178 (42.3)
	IIIN	263 (28.5)	112 (26.6)
	IIIM	72 (7.7)	51 (12.1)
	IV	39 (4.2)	20 (4.8)
	V	2 (0.2)	8 (1.9)
Smoked in pregnancy (n (%))
No		768 (84.9)	431 (77.2)	<0.001
Yes		137 (15.1)	127 (22.8)
Maternal asthma (n (%))
No		733 (78.7)	442 (76.2)	0.251
Yes		198 (21.3)	138 (23.8)
Maternal childhood eczema (n (%))
No		758 (81.5)	476 (82.1)	0.783
Yes		172 (18.5)	104 (17.9)
Maternal rhinitis (n (%))
No		539 (57.9)	353 (60.9)	0.254
Yes		392 (42.1)	227 (39.1)
Maternal atopy (n (%))
No		438 (53.0)	236 (57.0)	0.185
Yes		388 (47.0)	178 (43.0)
Height, cm (mean (SD))		163.5 (6.6)	162.7 (6.0)	0.020
BMI, kg/m2 (median, (IQR))		24.3 (22.0 -27.5)	24.1 (21.8 -27.4)	0.657
Fat mass, kg (median, (IQR))		20.3 (16.3 -25.9)	19.5 (15.7 -25.8)	0.116
Child’s characteristics
Gender (n (%))
Male		485 (51.6)	313 (53.4)	0.489
Female		455 (48.4)	273 (46.6)
Birth weight, kg (mean (SD))		3.440 (0.551)	3.420 (0.580)	0.615
Gestational age, weeks (median (IQR))		40.1 (39.0 -41.0)	40.0 (39.1 -41.0)	0.969
Mother smoked during child’s infancy (n (%))
No		768 (84.9)	431 (77.2)	<0.001
Yes		137 (15.1)	125 (22.8)

Numbers do not always add to the full column totals due to missing data

Binary outcomes were compared by χ² test, categorical outcomes by a χ² test for trend, and continuous variables using t-tests, after transformation where appropriate, or a ranksum test.

The median (IQR) maternal BMI was 24.3 (22.0-27.5) kg m⁻²; 261 (28.1%) mothers were overweight and 135 (14.5%) were obese. Median maternal pre-pregnancy fat mass was 20.3 (16.3-25.9) kg. The median period between recruitment and 11 week interviews was 67 weeks (32-106 weeks). The mean (SD) difference in BMI calculated from weight measured at 11 weeks’ gestation was 0.62 (1.62) kg m⁻² greater than that calculated from weight measured at recruitment, whilst BMI calculated from the weight that mothers self-reported at 11 weeks of pregnancy to have been their immediate pre-pregnancy weight was 0.34 (1.78) kg m⁻² less than that calculated from weight measured at recruitment; the respective correlation coefficients were 0.95 and 0.93. Both maternal BMI and maternal fat mass were positively associated with child’s birthweight (p<0.001), there was no significant association with infant adiposity change.

Wheeze was experienced by 559 children (59.9%), and 137 (14.6%) had wheeze at age six years. Wheezing was transient in 401 (42.9 %) and persistent/late in 158 children (16.9%) (Figure 1). Asthma had been diagnosed in 145 children (15.4%), of whom 100 (10.6 %) had current symptoms or asthma treatment. Technically acceptable spirometry was achieved by 804 children (85.5%); 489 (82.0%) of 596 children attending the clinic had acceptable eNO measurements (Figure 1).

Childhood wheeze

Maternal pre-pregnancy fat mass was positively associated with ever wheezing (RR 1.09 per 10 kg, p=0.003). This association remained after adjusting for potential confounders (RR 1.08 per 10 kg, p=0.007 - Model 1, basic confounders); results were similar when gestation, infant adiposity gain or child’s BMI aged 6 years where included in the model (Table 2). Maternal fat mass was not associated with current or ever asthma. Children experiencing wheeze ≤3 years appeared to account for most of the association between maternal fatness and ever wheezing as maternal fat mass was positively associated with transient wheeze (RR 1.13, p=0.002) but not with current or persistent wheeze. The association with transient wheeze remained after adjusting for potential confounders, gestation, infant adiposity gain and child’s BMI aged 6 years (Table 2, Models 1-4) and also when child’s BMI aged 3 was adjusted for (RR 1.01, p=0.02).

Table 2.

Relationship between maternal pre-pregnancy fat mass (kg) and wheeze and atopy phenotypes in the offspring at age 6 years

	Unadjusted analysis				Model 1				Model 2
Outcome	RR	(95% CI)	P-value	n	RR	(95% CI)	P-value	n	RR	(95% CI)	P-value	n
Ever wheeze	1.09	(1.03, 1.16)	0.003	921	1.08	(1.02, 1.15)	0.007	895	1.09	(1.03, 1.16)	0.002	895
Ever asthma	1.10	(0.93, 1.31)	0.27	927	1.05	(0.89, 1.24)	0.57	890	1.10	(0.93, 1.30)	0.28	890
Current wheeze	1.04	(0.86, 1.25)	0.68	927	1.06	(0.87, 1.29)	0.54	808	1.09	(0.90, 1.32)	0.39	808
Current asthma	1.14	(0.91, 1.43)	0.24	927	1.10	(0.89, 1.37)	0.39	918	1.14	(0.92, 1.41)	0.22	918
Transient wheeze	1.13	(1.05, 1.23)	0.002	764	1.11	(1.02, 1.20)	0.01	743	1.12	(1.03, 1.21)	0.006	743
Persistent wheeze	1.12	(0.96, 1.30)	0.14	526	1.08	(0.94, 1.24)	0.26	519	1.11	(0.98, 1.27)	0.11	519
Atopy	1.07	(0.91, 1.25)	0.43	681	1.14	(0.97, 1.35)	0.12	590	1.14	(0.97, 1.35)	0.12	590
					Model 3				Model 4
					RR	(95% CI)	P-value	n	RR	(95% CI)	P-value	n
Ever wheeze					1.1	(1.03, 1.17)	0.004	817	1.09	(1.03, 1.15)	0.004	893
Ever asthma					1.14	(0.96, 1.35)	0.13	823	1.06	(0.89, 1.28)	0.52	888
Current wheeze					1.03	(0.84, 1.28)	0.76	741	1.09	(0.89, 1.33)	0.40	806
Current asthma					1.17	(0.94, 1.45)	0.16	835	1.14	(0.91, 1.42)	0.27	915
Transient wheeze					1.11	(1.02, 1.21)	0.01	686	1.11	(1.02, 1.20)	0.01	741
Persistent wheeze					1.12	(0.97, 1.30)	0.13	478	1.10	(0.96, 1.27)	0.17	519
Atopy					1.21	(1.02, 1.44)	0.03	546	1.15	(0.97, 1.36)	0.12	590

Relative risk represents change in outcome per 10 kg of maternal pre-pregnancy fat mass.

Model 1 Adjusted for potential confounders significantly associated with the outcome, excluding child’s birthweight, gestation.

Ever wheeze-maternal education, asthma and rhinitis, child’s gender and age last breastfed; Ever asthma- maternal education, asthma and smoking in pregnancy, and child’s gender; Current wheeze-maternal education, asthma and atopy; Current asthma-maternal education and asthma; Transient wheeze-maternal height, parity, asthma and rhinitis, child’s gender and age last breastfed; Persistent wheeze-maternal education, asthma and rhinitis and child’s gender; Atopy-maternal social class, asthma and atopy, and child’s gender.

Model 2 adjusted for potential confounders significantly associated with the outcome, including child’s birthweight, gestation.

Ever wheeze-maternal education, asthma and rhinitis, child’s gender, age last breastfed and gestation; Ever asthma- maternal education, asthma, smoking in pregnancy and parity, child’s gender and gestation; Current wheeze-maternal education, asthma and atopy, child’s gender and gestation; Current asthma-maternal education and asthma, and child’s gestation; Transient wheeze-maternal height, parity, asthma and rhinitis, child’s gender, age last breastfed and gestation; Persistent wheeze-maternal education, asthma and rhinitis, child’s gender and gestation; Atopy-maternal social class, asthma and atopy, and child’s gender.

Model 3 adjusted for increase in adiposity between birth and 6 months and potential confounders significantly associated with the outcome (listed in Model 2) including child’s birthweight and gestation.

Model 4 adjusted for child’s BMI at age 6 years and potential confounders significantly associated with the outcome including child’s birthweight and gestation.

Similar associations were found between maternal pre-pregnancy BMI and wheeze outcomes (Table 3). Maternal BMI was positively associated with ever wheezing (RR 1.08 per 5 kg m⁻², p=0.006) and transient wheeze (RR 1.11 per 5 kg m⁻², p=0.003). These associations remained in each of the four adjusted models. Maternal BMI was not associated with ever or current asthma or current or persistent wheeze.

Table 3.

Relationship between maternal pre-pregnancy BMI and wheeze and atopy phenotypes in the offspring at age 6 years

	Unadjusted analysis				Model 1				Model 2
Outcome	RR	(95% CI)	P-value	n	RR	(95% CI)	P-value	n	RR	(95% CI)	P-value	n
Ever wheeze	1.08	(1.02, 1.14)	0.006	924	1.07	(1.01, 1.12)	0.01	897	1.08	(1.02, 1.13)	0.004	897
Ever asthma	1.07	(0.92, 1.24)	0.4	930	1.02	(0.87, 1.18)	0.84	892	1.06	(0.91, 1.24)	0.44	892
Current wheeze	0.99	(0.85, 1.16)	0.94	930	0.99	(0.84, 1.17)	0.94	809	1.02	(0.87, 1.20)	0.79	809
Current asthma	1.10	(0.91, 1.33)	0.31	930	1.06	(0.88, 1.27)	0.53	920	1.10	(0.92, 1.32)	0.30	920
Transient wheeze	1.11	(1.04, 1.18)	0.003	767	1.10	(1.03, 1.17)	0.006	746	1.11	(1.04, 1.18)	0.002	746
Persistent wheeze	1.08	(0.95, 1.24)	0.22	527	1.05	(0.93, 1.20)	0.42	519	1.09	(0.97, 1.24)	0.16	519
Atopy	1.08	(0.94, 1.24)	0.31	681	1.13	(0.98, 1.31)	0.10	589	1.13	(0.98, 1.31)	0.1	589
					Model 3				Model 4
					RR	(95% CI)	P-value	n	RR	(95% CI)	P-value	n
Ever wheeze					1.08	(1.02, 1.14)	0.009	819	1.07	(1.02, 1.13)	0.01	895
Ever asthma					1.08	(0.92, 1.26)	0.34	825	1.02	(0.86, 1.20)	0.85	890
Current wheeze					0.97	(0.82, 1.16)	0.77	742	1.02	(0.86, 1.22)	0.79	807
Current asthma					1.10	(0.91, 1.33)	0.31	837	1.10	(0.90, 1.34)	0.35	917
Transient wheeze					1.10	(1.03, 1.18)	0.006	689	1.10	(1.03, 1.18)	0.007	744
Persistent wheeze					1.09	(0.95, 1.25)	0.23	478	1.08	(0.95, 1.23)	0.25	519
Atopy					1.17	(1.00, 1.36)	0.05	545	1.14	(0.98, 1.32)	0.09	589

Relative risk represents change in outcome per 5 kg m⁻² of maternal pre-pregnancy BMI.

Models 1-4 adjusted for confounders as described in Table 2.

Maternal weight gain was not associated with respiratory outcome in the children (Tables S1 & S2).

Childhood atopy

Neither maternal fat mass (Table 2) nor BMI (Table 3) were associated with cutaneous sensitisation, before or after adjusting for confounders.

Lung function and eNO

Neither maternal fat mass nor BMI were associated with any measure of lung function, (Table 4). There were no associations after adjusting for confounders in any multivariable model. No associations, before or after adjustment, were found between either maternal fat mass or maternal BMI and eNO (Table S3).

Table 4.

Relationship between maternal pre-pregnancy fat mass (kg) and exhaled nitric oxide and lung function in the offspring at age 6 years

	Unadjusted analysis				Model 1				Model 2
	Beta	(95% CI)	P-value	n	Beta	(95% CI)	P-value	n	Beta	(95% CI)	P-value	n
FEV1 z-score	0.0349	(−0.0413, 0.1111)	0.37	793	0.0274	(−0.0476, 0.1025)	0.47	793	0.0230	(−0.0555, 0.1015)	0.56	784
FVC z-score	0.0433	(−0.0439, 0.1306)	0.33	793	0.0301	(−0.0586, 0.1188)	0.5	765	0.0301	(−0.0586, 0.1188)	0.5	765
FEF25-75% z-score	0.0163	(−0.0796, 0.1122)	0.74	793	0.0181	(−0.0775, 0.1137)	0.71	793	0.0071	(−0.0886, 0.1028)	0.88	793
FEV1/FVC z-score	−0.0190	(−0.1043, 0.0663)	0.66	793	−0.0130	(−0.0998, 0.0739)	0.77	765	−0.0130	(−0.0998, 0.0739)	0.77	765
Exhaled nitric oxide	−0.0575	(−0.1667, 0.0517)	0.30	482	−0.0908	(−0.2018, 0.0203)	0.11	477	−0.0908	(−0.2018, 0.0203)	0.11	477
					Model 3				Model 4
					Beta	(95% CI)	P-value	n	Beta	(95% CI)	P-value	n
FEV1 z-score					0.0115	(−0.0702, 0.0932)	0.78	721	0.0122	(−0.0684, 0.0928)	0.76	784
FVC z-score					0.0287	(−0.0625, 0.1199)	0.54	713	0.0001	(−0.0913, 0.0916)	0.99	765
FEF25-75% z-score					−0.0035	(−0.1031, 0.0961)	0.94	725	0.0160	(−0.0829, 0.1149)	0.75	793
FEV1/FVC z-score					−0.0293	(−0.1181, 0.0594)	0.51	713	0.0055	(−0.0846, 0.0956)	0.9	765
Exhaled nitric oxide					−0.0989	(−0.2152, 0.0174)	0.09	434	−0.0889	(−0.2029, 0.0250)	0.12	477

Regression coefficient represents change in outcome per 10 kg of maternal pre-pregnancy fat mass.

Model 1 Adjusted for potential confounders significantly associated with the outcome, excluding child’s birthweight and gestation.

FEV₁-child’s gender; FVC-maternal smoking in pregnancy and rhinitis, and child’s gender; FEF_25-75%-maternal parity and child’s gender; FEV₁/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema.

Model 2 adjusted for potential confounders significantly associated with the outcome, including child’s birthweight and gestation.

FEV₁-maternal height, and child’s gender and birthweight; FVC-maternal smoking in pregnancy and rhinitis, and child’s gender; FEF_25-75%-maternal parity and child’s gender and gestation; FEV₁/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema.

Model 3 adjusted for increase in adiposity between birth and 6 months and potential confounders significantly associated with the outcome including child’s birthweight and gestation (listed in Model 2).

Model 4 adjusted for child’s BMI at age 6 years and potential confounders significantly associated with the outcome including child’s birthweight and gestation (listed in Model 2).

All the above results for wheeze, atopy, lung function and eNO were unchanged by considering BMI as a categorical variable or by limiting the analysis to women who became pregnant within 1 year of their initial interview.

Infant adiposity gain

Infant adiposity gain was associated with persistent wheeze but significance was reduced after adjusting for likely confounders (RR 1.14, p=0.05). Similar results were seen after other potential confounders were adjusted for: gestation (RR 1.14, p=0.04 – Model 2), BMI aged 3 years (RR 1.10, p=0.16 – Model 3) and BMI aged 6 years (RR 1.14, p=0.05 – Model 4). There were no significant associations with ever or current asthma, or ever or current wheeze. In contrast to the findings for maternal obesity, no association was found between infant adiposity gain and transient wheeze (Table S4). There were weak inverse associations between infant adiposity gain and both FEF_25-75% and FEV₁/FVC (p=0.02 for each) (Table S5).

DISCUSSION

This is the first study to measure the association between pre-pregnancy measurements of maternal adiposity and longitudinal childhood wheeze phenotypes. Greater maternal fat mass and BMI were associated with increased childhood wheeze risk. There were significant positive associations with transient wheeze but none with persistent wheeze or asthma. This has potentially important public health implications since individuals who wheeze in infancy more commonly develop chronic obstructive airways disease as adults. Adjusting for infant adiposity or child’s BMI at age 3 or 6 years did not reduce the association with transient wheeze. There were no associations between maternal fatness and atopy, eNO or spirometry.

Previous studies have used BMI to estimate adiposity. Women were recruited after conception and pre-pregnancy weight self-reported often several months after birth;(6) in some studies neither height nor weight was measured.(7) To provide an objective measure of adiposity, uncomplicated by variation in BMI with body type(25) or by alterations in fat distribution during pregnancy(26) we estimated maternal fat mass from pre-pregnancy skinfold thicknesses. BMI calculated from weight measured pre-pregnancy and from estimated pre-pregnancy weight self-reported at 11 weeks of pregnancy were closely correlated. Moreover, the study’s main findings were unchanged by restricting analyses to women for whom less than a year had elapsed between initial and pregnancy interviews. Together these findings suggest that the measured pre-pregnancy values are likely to accurately reflect relative maternal fatness immediately before and during early pregnancy.

The finding of increased wheeze in association with greater maternal adiposity is consistent with previous studies. Associations have been found between higher maternal BMI and increased wheeze at 18 months,(7) 3 years (8, 27) and 8 years,(6) and also in adolescence.(5) Few studies have assessed objective measures of atopy in relation to maternal adiposity. Kumar et al found an inverse relationship between maternal pre-pregnancy BMI and cord blood total IgE but no association with food allergy or eczema,(8) whilst Scholtens et al found no association with specific IgE to inhalant allergens.(6) We have found neither an association between maternal adiposity and cutaneous sensitisation nor eosinophilic airway inflammation measured by eNO. Furthermore, although cross-sectional adult data have suggested an association between adiposity and atopy,(28) cross-sectional studies in childhood provide no evidence for this.(29)

The positive association between maternal adiposity and transient wheeze is unique to this study as no other study has assessed longitudinal wheeze phenotypes. Our finding is supported by studies assessing wheeze in early childhood.(7, 8, 27) The lack of longitudinal studies means that evidence supporting an association between maternal adiposity and persistence of wheeze symptoms in older children is less conclusive. No association was found between maternal adiposity and doctor-diagnosed asthma in our study, although our power was less for this outcome than for transient or for ever wheeze. The only study to date to have found such an association, did so in infancy when asthma is difficult to diagnose.(27)

Two studies(5, 6) have reported associations with self-reported asthma, although only after considering effect modification by genetic predisposition. However these studies’ results were contradictory; Scholtens found maternal adiposity associated with asthma only in children considered predisposed due to parental asthma or allergy,(6) whilst Patel found this association to be strongest in children without a parental history of atopy.(5) Subtle differences in the phenotypic characteristics of the individuals assigned to the current wheeze grouping may have existed between the populations and age groups considered in each of these studies. Similarly differences in the nature and extent of residual confounding associated with the measured or estimated values of maternal adiposity used may explain, in part, the conflicting results.

Previous studies report an effect of maternal adiposity beyond that mediated by pregnancy or birth complications,(7) whilst this and other studies suggest that a direct effect beyond that of an association with childhood obesity is possible. We were unable to confirm our previous finding of increased wheeze risk in association with greater infant adiposity gain,(13) possibly due to reduced power as fewer children were seen at 6 than at 3 years. Nevertheless it was felt important to correct for potential confounding by infant adiposity gain. Adjustment for infant adiposity gain or childhood BMI did not reduce the association between maternal adiposity and transient wheeze, suggesting that the effect of maternal obesity is not mediated by childhood adiposity. Indeed the contrasting findings of an association between maternal obesity and transient wheeze and a borderline association between infant weight gain and persistent wheeze suggests separate mechanisms may underlie these associations.

This study did not detect any association between maternal pregnancy weight gain, according to Institute of Medicine categorisation, and any wheeze, atopy or lung function outcome. This is surprising given that excessive pregnancy weight gain has been shown to be associated with infant adiposity and has been proposed to predispose to a number of obesity-associated adverse outcomes.(30) Possibly, categorisation according to weight gain throughout pregnancy is not sensitive to the effects of weight gain during periods of particular significance for determining fetal health and development. Alternatively, absolute maternal fatness may determine fetal exposure and childhood outcome more directly than rate of weight gain. Serum levels of proinflammatory cytokines are known to be higher in obese pregnant women than pregnant women of normal weight(31) and it has been proposed that an increased inflammatory response might affect fetal immunological or pulmonary development. Other factors associated with obesity include high glucose, insulin, lipid and leptin levels.(4, 32) Although observational studies cannot determine causality, careful characterisation of wheeze phenotypes may suggest mechanisms by which maternal adiposity might predispose to childhood wheeze. In the absence of an association with atopy, there is little to support an effect of maternal adiposity upon atopic immunity.

Transient childhood wheeze is believed to arise during viral infections in individuals predisposed to airways obstruction. It is possible that maternal obesity might affect airway development. Leptin is elevated in obesity(32) and leptin receptors in the lung may mediate effects upon lung growth.(33) However, although lung function is believed to track across the life-course, no association was found between maternal adiposity and spirometry at 6 years. This may reflect a transient effect upon lung function or there may be subtle differences in airway function that the spirometric indices measured could not detect. It is possible that lung function effects are particularly important in the transient wheeze phenotype and that a significant association may be found in a cohort large enough to support analysis of the relationship between adiposity and lung function stratified by wheeze phenotype.

Alternatively, maternal adiposity may confer vulnerability to transient wheeze via an effect upon severity of viral infection, perhaps by an effect upon innate immunity similar to that proposed to explain reported associations between prenatal vitamin D exposure and childhood wheeze.(34) Certainly there is data to support increased respiratory infection in overweight individuals.(35)

This study’s strength lies in the robust measurement of maternal fat mass and BMI in a longitudinal birth-cohort. The wheeze outcomes were assessed using standardised questions permitting comparison with other studies. Uniquely, this study considered the influence of early infant adiposity gain upon outcome and also objectively assessed lung function and skin sensitisation. Although observational studies are inherently vulnerable to response bias, the response rate was good in this study and neither maternal pre-pregnancy fat mass nor BMI differed significantly between participants and non-participants. Furthermore, the relationship between maternal adiposity and childhood wheeze was one of many objectives of a broader study assessing the effect of maternal nutrition upon childhood growth and health, it is unlikely that parental health knowledge may have affected participation. A hurdle to interpreting the data surrounds identifying the relevant exposure. Ideally measurements might be taken in early pregnancy rather than pre-pregnancy, but changes to maternal body composition vary between women and there are no standardised measurements or reference charts for pregnancy. Critical windows in pregnancy may also be relevant. Despite these challenges we find that the association with wheeze holds whether measuring BMI or adiposity estimated from skin fold thickness prior to pregnancy.

In conclusion, we found that greater maternal pre-pregnancy fat mass and BMI were associated with an increased risk of transient wheeze in childhood. There was no evidence for an effect of maternal adiposity upon childhood atopy but the association with transient wheeze suggests an effect upon airway development.

• What is the key question? Does maternal body composition influence the presence of asthma and wheeze phenotypes in children at age 6 years.

• What is the bottom line? This study uses directly measured BMI and estimated maternal fat mass to demonstrate an association between maternal obesity and the transient childhood wheeze phenotype.

• Why read on? This is the first study to investigate the association of prospectively measured of maternal body composition with longitudinal wheeze outcomes in childhood.